Aleradin 5mg medicine reduces symptoms of seasonal allergic rhinitis, urticaria (3 blisters x 10 tablets)

Dosage form Film bag tablets
Specifications Box of 3 blisters x 10 tablets
Ingredient Desloratadine
Indication Urticaria, itching, atopic dermatitis, contact dermatitis, stuffy nose

Ingredient

Composition information	Content
Desloratadine	5mg

Uses

Indications

Aleradin drugs are indicated to reduce symptoms of allergic rhinitis, urticaria.

Pharmacokology

Desloratadine is a mainly oral activity of Loratadin, which is H1 antihistamine that does not cause drowsiness.

pharmacokinetic

absorption

In healthy volunteers, after taking a dose of 5 mg/day for 10 days, desloratadine is absorbed quickly with an average time to reach maximum concentration in plasma (TMAX) is about 3 hours after drinking, the average peak concentration in plasma (CMAX) and the area under the concentration - time (AUC) curve (AUC) is recorded as 4 ng/mL. Food and grapefruit juice have no effect on the bioavailability of desloratadine (CMAX and AUC).

Distribution

About 82% to 87% Desloratadine and 85% to 89% 3 - Hydroxydesloratadine attached to plasma proteins. The attachment to the protein of desloratadine and 3 - hydroxydesloratadine does not change in the individual failure.

Metabolism

Desloratadine (Loratadine's main metabolites) is strongly metabolized to 3 - hydroxydesloratadine is an active metabolic substance, then glucuronid will be. The enzymes are responsible for the formation of 3 - hydroxydesloratadine. Clinical test data shows that a small part of the patient population has a reduction in the ability to form 3 - hydroxydesloratadine and slow metabolites of desloratadine. In pharmacokinetic studies (n = 1087), about 7% of subjects have slow metabolism of desloratadine (identified as objects with AUC ratio of 3 - Hydroxydesloratadine compared to desloratadine below 0.1 or the subject of semi -destructor Desloratadine over 50 hours).

The frequency of objects with slow metabolic in black people (about 20% of black people are slowly metabolized in pharmacokinetic studies, n = 276). The average plasma concentration (AUC) of the desloratadine in those who metabolize slowly is about 6 times greater than those who are not slow metabolites. It is impossible to identify people with slow metabolism for desloratadine and in these individuals will have auc of desloratadine in plasma higher after taking desloratadine at the right dose. Although there are no pharmacokinetic studies on this issue, patients with slow metabolism for desloratadine will be more sensitive to adultery effects related to dosage.

Elimination

Desloratadine average half -life is 27 hours. The values of the concentration of CMAX and AUC peaks increase the ratio at a single dose after a single dose, between 5 and 20mg. The level of accumulation after drinking 14 days is in parallel with the half -life and the frequency of dosage. A study of mass balance in humans shows that there is a restoration of about 87% of the 14C dose - Desloratadine (Desloratadine is found by C14) found in urine and feces, such as metabolic products. Analysis 3 - Hydroxydesloratadine in plasma also shows the same values of TMAX and the semi -cancellation time, as with the desloratadine.

Before taking Aleradin 5mg medicine reduces symptoms of seasonal allergic rhinitis, urticaria (3 blisters x 10 tablets)

How to use

oral drugs. Drink with or not ate meals to reduce symptoms related to allergic rhinitis (including non -continuous allergic rhinitis and prolonged allergic rhinitis) and urticaria.

Dosage

Adults and teenagers (12 years or older)

Take 1 capsule daily, during or outside meals to reduce symptoms related to allergic rhinitis (including allergic rhinitis in batches and persistent) and urticaria.

There is little experience from clinical trials about the use of desloratadin for teenagers from 12 to 17 years old.

It is necessary to control all allergic rhinitis (symptoms for less than 4 days a week or less than 4 weeks) depending on the patient's history evaluation results. Should stop taking the drug after the symptoms are out of symptoms and use the drug again when the symptoms reappear.

With persistent allergic rhinitis (symptoms for 4 days or more per week and lasting for more than 4 weeks), it is possible to treat patients continuously during exposure to allergens.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when using overdose?

Recommendation for symptomatic treatment and supportive treatment.

In a multi -dose clinical trial, the patient was used up to 45mg of desloratadin (9 times the usual doses), no clinical abnormal reactions.

Desloratadin cannot be removed from circulation through hemolysis. It is unclear whether the drug is eliminated through the peritoneal fertilizer.

What to do when forgetting a dose?

Side Effects

When using Aleradin you may experience unwanted effects (ADR).

In clinical trials on some indications including allergic rhinitis and chronic spontaneous urticaria, when using the recommended dose of 5mg daily, Aleradin's undesirable effects are recorded in the group of drugs higher than 3% compared to the placebo group. The most common adverse reactions are fatigue (1.2%), dry mouth (0.8%) and headache (0.6%). In a clinical trial of over 578 patients of teenagers, from 12 to 17 years old, the most common adverse reaction was the headache that appeared in 5.9% of patients using Aleradin and 6.9% in placebo patients.

Other unwanted effects have been recorded with very rare frequency in the process of post -marketing monitoring listed below:

Mental disorders: hallucinations. liver.

Warnings

Contraindicated

Aleradin is contraindicated in case of hypersensitivity to desloratadin or any excipients of the drug or hypersensitivity to Loratadin.

Precautions when using

The efficiency and safety of Aleradin tablets in children under 12 years old has not been proven.

In the case of patients with severe renal failure, caution should be used when using aleradin.

Patients with rare genetic diseases are galactose intolerance, lactase lactase deficiency or Glucose/Galactose abutment should not use this drug.

Patients should stop taking the drug in the following cases:

There are abnormal signs during use.

After a period of use, the disease has no positive changes.

The ability to drive and operate machinery

In clinical trials assessing the effect of Aleradin on driving ability, not detecting the effect of reducing the driving capacity of the drug. However, it is necessary to notify the patient that a very rare number of patients have drowsiness when taking the drug, which can affect the ability to drive or operate machinery.

Pregnancy

Aleradin does not cause teratogenic tests in animal tests. The safety of the drug when used during pregnancy has not been proven. Therefore, it is not recommended to use aleradin during pregnancy.

Breastfeeding period

Aleradin is secreted into breast milk, so it is not recommended to use this drug in nursing women.

Drug interaction

has not recorded any clinical interactions in the testing tests simultaneously aleradin tablets along with erythromycin or ketoconazole.

In a clinical trial, drinking Aleradin at the same time with alcohol does not affect the effect of reducing the activity of alcohol.

Storage

The preservation of drugs is important to ensure efficiency during use. The drug should be stored in the box at room temperature at a temperature of not more than 25 degrees Celsius and stay out of reach of children.

Do not use the drug when expired and have signs of mold, discoloration.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.